Molecular Docking Study of the Binding Interaction of Hydroxychloroquine, Dexamethasone and Other Anti-Inflammatory Drugs with SARS-CoV-2 Protease and SARS-CoV-2 Spikes Glycoprotein
Aims: The outbreak of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still accountable for millions of deaths worldwide and declared as a global pandemic by the World Health Organisation. Despite efforts, there is still limited evidence available on a successful potent inhibitor with a low toxicity profile that can aid in the prevention and/or treatment of COVID-19. This study will focus on four main aspects: 1) screening 19 Food Drug and Administration (FDA) approved drugs using computational molecular docking; 2) assessing drug toxicity profiles using biological data; 3) recommending potential therapies against COVID-19 and 4) supplementing currently used therapies. Methods: 19 FDA approved drugs were investigated against the crystal structure of SARS-CoV-2 protease (6LU7) and SARS-CoV-2 glycoprotein (6VXX) using a computational molecular docking software, Molecular Operating Environment (MOE). Separately, on MOE, 6LU7 and 6VXX were loaded, prepared, and the binding pockets located. The drug’s canonical SMILES were imported, minimised, and docked on the prepared proteins using a search algorithm to establish the highest stability conformation. Drugs were ranked depending on binding properties and biological data to assess safety; steric clashes and voids in the binding site were also analysed. Results and discussion: Out of the nineteen (19) FDA approved drugs, 18 inhibited 6LU7 and 13 inhibited 6VXX. High-ranked drugs based on binding properties for 6LU7 were hydroxychloroquine, dexamethasone, naproxen, etoricoxib, and ibuprofen. For 6VXX were hydroxychloroquine, celecoxib, etoricoxib, meloxicam, and parecoxib. Considering safety profile, the top 3 drugs in descending order for 6LU7 were etoricoxib, naproxen and dexamethasone and for 6VXX were etoricoxib, meloxicam, and parecoxib. Compared to the literature, the results were consistent for dexamethasone which was effective against 6LU7. However, for hydroxychloroquine and ibuprofen, there was conflicting literature regarding safety and efficacy. Conclusion and future work: The findings suggest that against COVID-19 etoricoxib might be effective as a therapeutic and prophylactic measure. Naproxen and dexamethasone would be more effective as treatment only while meloxicam and parecoxib as prophylaxis. However, future studies are needed to validate these findings. Compared to previous literature, the findings in this study also support the use of dexamethasone
References
[1]
World Health Organization (2020) Coronavirus Disease (COVID-19).
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2]
World Health Organization (2021) Weekly Epidemiological Update—5 January 2021.
https://www.who.int/publications/m/item/weekly-epidemiological-update---5-january-2021
[3]
Vlachakis, D., Papakonstantinou, E., Mitsis, T., Pierouli, K., Diakou, I., Chrousos, G., et al. (2020) Molecular Mechanisms of the Novel Coronavirus SARS-CoV-2 and Potential Anti-COVID19 Pharmacological Targets since the Outbreak of the Pandemic. Food and Chemical Toxicology, 146, Article ID: 111805.
https://doi.org/10.1016/j.fct.2020.111805
[4]
Zhao, Z., Wang, Y., Qiu, L., Fu, T., Yang, Y., Peng, R., et al. (2020) New Insights from Chemical Biology: Molecular Basis of Transmission, Diagnosis, and Therapy of SARS-CoV-2. CCS Chemistry, 3, 1501-1528.
https://doi.org/10.31635/ccschem.020.202000322
[5]
Ye, Z.W., Yuan, S., Yuen, K.S., Fung, S.Y., Chan, C.P. and Jin, D.Y. (2020) Zoonotic origins of Human Coronaviruses. International Journal of Biological Sciences, 16, 1686. https://doi.org/10.7150/ijbs.45472
[6]
Satarker, S., Ahuja, T., Banerjee, M., Dogra, S., Agarwal, T. and Nampoothiri, M. (2020) Hydroxychloroquine in COVID-19: Potential Mechanism of Action against SARS-CoV-2. Current Pharmacology Reports, 6, 203-211.
https://doi.org/10.1007/s40495-020-00231-8
[7]
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020) A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine, 382, 727-733. https://doi.org/10.1056/NEJMoa2001017
[8]
Gupta, M.K., Vemula, S., Donde, R., Gouda, G., Behera, L. and Vadde, R. (2020) In-Silico Approaches to Detect Inhibitors of the Human Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel. Journal of Biomolecular Structure and Dynamics, 1-11. https://doi.org/10.1080/07391102.2020.1751300
[9]
Boopathi, S., Poma, A.B. and Kolandaivel, P. (2020) Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug Promises and Rule out against Its treatment. Journal of Biomolecular Structure and Dynamics, 1-10.
https://doi.org/10.1080/07391102.2020.1758788
[10]
Chan, J.F.W., Kok, K.H., Zhu, Z., Chu, H., To, K.K.W., Yuan, S., et al. (2020) Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan. Emerging microbes & infections, 9, 221-236. https://doi.org/10.1080/22221751.2020.1719902
[11]
Al-Horani, R.A., Kar, S. and Aliter, K.F. (2020) Potential anti-COVID-19 Therapeutics That Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. International Journal of Molecular Sciences, 21, Article No. 5224. https://doi.org/10.3390/ijms21155224
[12]
Glowacka, I., Bertram, S., Müller, M.A., Allen, P., Soilleux, E., Pfefferle, S., et al. (2011) Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response. Journal of Virology, 85, 4122-4134.
https://doi.org/10.1128/JVI.02232-10
[13]
Nishiga, M., Wang, D.W., Han, Y., Lewis, D.B. and Wu, J.C. (2020) COVID-19 and Cardiovascular Disease: From Basic Mechanisms to Clinical Perspectives. Nature Reviews Cardiology, 17, 543-558. https://doi.org/10.1038/s41569-020-0413-9
[14]
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H. and Thiel, V. (2020) Coronavirus Biology and Replication: Implications for SARS-CoV-2. Nature Reviews Microbiology, 19, 155-170. https://doi.org/10.1038/s41579-020-00468-6
[15]
Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., et al. (2020) COVID-19 Diagnosis and Management: A Comprehensive Review. Journal of Internal Medicine, 288, 192-206. https://doi.org/10.1111/joim.13091
[16]
Parasher, A. (2020) COVID-19: Current Understanding of Its Pathophysiology, Clinical Presentation and Treatment. Postgraduate Medical Journal, 1-9.
https://doi.org/10.1136/postgradmedj-2020-138577
[17]
Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., et al. (2020) Aberrant Pathogenic GM-CSF+ T Cells and Inflammatory CD14+ CD16+ Monocytes in Severe Pulmonary Syndrome Patients of a New Coronavirus. BioRxiv.
https://doi.org/10.1101/2020.02.12.945576
[18]
Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., et al. (2020) COVID-19, Cytokines and Immunosuppression: What Can We Learn from Severe Acute Respiratory Syndrome? Clinical and Experimental Rheumatology, 38, 337-342.
[19]
Rainer, T.H. (2004) Severe Acute Respiratory Syndrome: Clinical Features, Diagnosis, and Management. Current Opinion in Pulmonary Medicine, 10, 159-165.
https://doi.org/10.1097/00063198-200405000-00003
[20]
Tsang, K.W. and Lam, W.K. (2003) Management of Severe Acute Respiratory Syndrome: the Hong Kong University Experience. American Journal of Respiratory and Critical Care Medicine, 168, 417-424. https://doi.org/10.1164/rccm.2305012
[21]
Food and Drug Administration (2020) Emergency Use Authorization.
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
[22]
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 56, Article ID: 105949.
https://doi.org/10.1016/j.ijantimicag.2020.105949
[23]
Pastick, K.A., Okafor, E.C., Wang, F., Lofgren, S.M., Skipper, C.P., Nicol, M.R., et al. (2020) Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 7, ofaa130.
https://doi.org/10.1093/ofid/ofaa130
[24]
Fantini, J., Chahinian, H. and Yahi, N. (2020) Synergistic Antiviral Effect of Hydroxychloroquine and Azithromycin in Combination against SARS-CoV-2: What Molecular Dynamics Studies of Virus-Host Interactions Reveal. International Journal of Antimicrobial Agents, 56, Article ID: 106020.
https://doi.org/10.1016/j.ijantimicag.2020.106020
[25]
Sunny, J.S., Balachandran, S., Solaipriya, S. and Saleena, L.M. (2020) Comparison of Random and Site Directed Mutation Effects on the Efficacy between Lead SARS-CoV2 Anti-Protease Drugs Indinavir and Hydroxychloroquine. Research Square. (Preprint) https://doi.org/10.21203/rs.3.rs-22082/v1
[26]
World Health Organization (2020) “Solidarity” Clinical Trial for COVID-19 Treatments.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
[27]
Sanders, J.M., Monogue, M.L., Jodlowski, T.Z. and Cutrell, J.B. (2020) Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 323, 1824-1836. https://doi.org/10.1001/jama.2020.6019
[28]
Rosenberg, E.S., Dufort, E.M., Udo, T., Wilberschied, L.A., Kumar, J., Tesoriero, J., et al. (2020) Association of Treatment with Hydroxychloroquine or Azithromycin with in-Hospital Mortality in Patients with COVID-19 in New York State. Jama, 323, 2493-2502. https://doi.org/10.1001/jama.2020.8630
[29]
Inciardi, R.M., Lupi, L., Zaccone, G., Italia, L., Raffo, M., Tomasoni, D., et al. (2020) Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 5, 819-824. https://doi.org/10.1001/jamacardio.2020.1096
[30]
Zoorob, R. and Cender, D. (1998) A Different Look at Corticosteroids. American Family Physician, 58, 443-450.
[31]
Johnson, R.M. and Vinetz, J.M. (2020) Dexamethasone in the Management of Covid-19: Preliminary Trial Results Are Mostly Good News, But Timing Is Everything. BMJ, 370, Article No. m2648. https://doi.org/10.1136/bmj.m2648
https://www.bmj.com/content/bmj/370/bmj.m2648.full.pdf
[32]
World Health Organization (2020) Coronavirus Disease (COVID-19): Dexamethasone.
https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-dexamethasone
[33]
Shang, L., Zhao, J., Hu, Y., Du, R. and Cao, B. (2020) On the Use of Corticosteroids for 2019-nCoV Pneumonia. Lancet, 395, 683-684.
https://doi.org/10.1016/S0140-6736(20)30361-5
[34]
Ahmed, M.H. and Hassan, A. (2020) Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): A Review. SN Comprehensive Clinical Medicine, 2, 2637-2646. https://doi.org/10.1007/s42399-020-00610-8
[35]
Day M. (2020) Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists. BMJ, 368, Article No. m1086.
https://doi.org/10.1136/bmj.m1086
[36]
World Health Organization (2020) The Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Patients with COVID-19: Scientific Brief.
https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19
[37]
Yousefifard, M., Zali, A., Zarghi, A., Madani Neishaboori, A., Hosseini, M. and Safari, S. (2020). Non-Steroidal Anti-Inflammatory Drugs in Management of COVID-19: A Systematic Review on Current Evidence. International Journal of Clinical Practice, 74, e13557. https://doi.org/10.1111/ijcp.13557
[38]
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, U., Sauerhering, L., et al. (2020) Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved α-Ketoamide Inhibitors. Science, 368, 409-412.
https://doi.org/10.1126/science.abb3405
[39]
Lee, H.S. and Zhang, Y. (2012) BSP-SLIM: A Blind Low-Resolution Ligand-Protein Docking Approach Using Predicted Protein Structures. Proteins, 80, 93-110.
https://doi.org/10.1002/prot.23165
[40]
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., et al. (2020) Structure of Mpro from SARS-CoV-2 and Discovery of Its Inhibitors. Nature, 582, 289-293.
https://doi.org/10.1038/s41586-020-2223-y
[41]
Singh, D.D., Han, I., Choi, E.H. and Yadav, D.K. (2020) Recent Advances in Pathophysiology, Drug Development and Future Perspectives of Sars-Cov-2. Frontiers in Cell and Developmental Biology, 8, Article No. 1124.
[42]
Liu, X., Zhang, B., Jin, Z., Yang, H. and Rao, Z. (2020) 6LU7: The Crystal Structure of COVID-19 Main Protease in Complex with an Inhibitor N3.
http://www.rcsb.org/structure/6LU7
http://dx.doi.org/10.2210/pdb6lu7/pdb
[43]
Tortorici, M.A. and Veesler, D. (2019) Structural Insights into Coronavirus Entry. Advances in Virus Research, 105, 93-116.
https://doi.org/10.1016/bs.aivir.2019.08.002
[44]
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T. and Veesler, D. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181, 281. http://dx.doi.org/10.1016/j.cell.2020.02.058
[45]
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., et al. (2020) 6VXX: Structure of the SARS-CoV-2 Spike Glycoprotein (Closed State).
http://dx.doi.org/10.2210/pdb6vxx/pdb
https://www.rcsb.org/structure/6vxx
[46]
Sliwoski, G., Kothiwale, S., Meiler, J. and Lowe Jr., E.W. (2013) Computational Methods in Drug Discovery. Pharmacological Reviews, 66, 334-395.
https://doi.org/10.1124/pr.112.007336
[47]
Dueva, E., Singh, K., Kalyta, A., LeBlanc, E., Rennie, P.S. and Cherkasov, A. (2018) Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor. Molecules, 23, Article No. 2967.
https://doi.org/10.3390/molecules23112967
[48]
Meng, X.Y., Zhang, H.X., Mezei, M. and Cui, M. (2011) Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. Current Computer-Aided Drug Design, 7, 146-157. https://doi.org/10.2174/157340911795677602
[49]
Ferreira, L.G., Dos Santos, R.N., Oliva, G. and Andricopulo, A.D. (2015) Molecular Docking and Structure-Based Drug Design Strategies. Molecules, 20, 13384-13421.
https://doi.org/10.3390/molecules200713384
[50]
DrugBank. https://go.drugbank.com
[51]
https://www.medicines.org.uk/
[52]
Omorogbe, P. (2020) Coronavirus: We Are Now Receiving Patients Suffering from Chloroquine Poisoning, Says Lagos Govt, NCDC Cautions Nigerians.
https://tribuneonlineng.com/coronavirus-we-are-now-receiving-patients-suffering-from-chloroquine-poisoning-says-lagos-govt-ncdc-cautions-nigerians/
[53]
Vigdor, N. (2020) Man Fatally Poisons Himself While Self-Medicating for Coronavirus, Doctor Says.
https://www.nytimes.com/2020/03/24/us/chloroquine-poisoning-coronavirus.html
[54]
Chary, M.A., Barbuto, A.F., Izadmehr, S., Hayes, B.D. and Burns, M.M. (2020) COVID-19: Therapeutics and Their Toxicities. Journal of Medical Toxicology, 16, 284-294. https://doi.org/10.1007/s13181-020-00777-5
[55]
Giles, A.J., Hutchinson, M.K.N., Sonnemann, H.M., Jung, J., Fecci, P.E., Ratnam, N.M., et al. (2018) Dexamethasone-Induced Immunosuppression: Mechanisms and Implications for Immunotherapy. Journal for Immunotherapy of Cancer, 6, Article No. 51. https://doi.org/10.1186/s40425-018-0371-5
[56]
Wang, Y., Jiang, W., He, Q., Wang, C., Wang, B., Zhou, P., et al. (2020) Early, Low-Dose and Short-Term Application of Corticosteroid Treatment in Patients with Severe COVID-19 Pneumonia: Single-Center Experience from Wuhan, China. medRxiv. (Preprint) https://doi.org/10.1101/2020.03.06.20032342
[57]
Obach, R.S., Walker, G.S. and Brodney, M.A. (2016) Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability. Drug Metabolism and Disposition, 44, 634-646.
https://doi.org/10.1124/dmd.116.069310
[58]
European Medicines Agency (2020) EMA Gives Advice on the Use of Non-Steroidal Antiinflammatories for COVID-19. European Medicines Agency, Amsterdam.
https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19_en.pdf
[59]
Sostres, C., Gargallo, C.J. and Lanas, A. (2013) Nonsteroidal Anti-Inflammatory Drugs and Upper and Lower Gastrointestinal Mucosal Damage. Arthritis Research & Therapy, 15, Article No. 53. https://doi.org/10.1186/ar4175
Zhuang, W.R., Wang, Y., Cui, P.F., Xing, L., Lee, J., Kim, D., et al. (2019) Applications of π-π Stacking Interactions in the Design of Drug-Delivery Systems. Journal of Controlled Release, 294, 311-326. https://doi.org/10.1016/j.jconrel.2018.12.014
[62]
Liao, S.M., Du, Q.S., Meng, J.Z., Pang, Z.W. and Huang, R.B. (2013) The Multiple Roles of Histidine in Protein Interactions. Chemistry Central Journal, 7, Article No. 44. https://doi.org/10.1186/1752-153X-7-44
[63]
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., et al. (2020) Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods. Acta Pharmaceutica Sinica B, 10, 766-788.
https://doi.org/10.1016/j.apsb.2020.02.008
[64]
Qamar, M., Alqahtani, S., Alamri, M. and Chen, L. (2020) Structural Basis of SARS-CoV-2 3CLpro and anti-COVID-19 Drug Discovery from Medicinal Plants. Journal of Pharmaceutical Analysis, 10, 313-319.
https://doi.org/10.1016/j.jpha.2020.03.009
